Articles by Patricia Van Arnum - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

  • Search
  • Suppliers
  • Careers

Enter a company or product name

Keyword Location
About Search
Articles by Patricia Van Arnum

Patricia Van Arnum

Executive Editor, Pharmaceutical Technology

Articles
A Look Ahead for Custom Manufacturing and Pharma
January 2, 2014

Emerging markets are an engine for growth in the custom-manufacturing and pharma markets.

The Future of Dosage Forms
January 2, 2014

How will the move to more specialized and personalized medicines impact drug delivery and dosage forms?

Bristol-Myers Squibb To Sell Diabetes Business to AstraZeneca
December 19, 2013

Bristol-Myers Squibb agrees to sell global diabetes business to AstraZeneca for $2.7 billion upfront plus an addition $1.4 billion in potential regulatory- and sales-based milestone payments.

AstraZeneca Issues Statement on Competitor to Nexium
December 18, 2013

AstraZeneca issues a statement regarding the launch of esomeprazole strontium in the United States.

Biogen Idec, Samsung Bioepis Target Anti-TNF Biosimilars in Europe
December 18, 2013

Biogen and Samsung Bioepis, a joint venture between Samsung Biologics and Biogen Idec, advance plans for anti-TNF biosimilar product candidates.

Pfizer, Teva Settle Patent Litigation on Viagra
December 18, 2013

Pfizer settles its litigation against Teva Pharmaceuticals regarding Pfizer's patent covering the use of Viagra.

Teva Releases Financial Guidance Dependent on Copaxone Generic Competition
December 12, 2013

Teva Pharmaceutical Industries releases a financial outlook for 2014 based on two possible scenarios concerning its multiple-sclerosis drug Copaxone (glatiramer acetate).

GlaxoSmithKline To Invest in UK-Based Manufacturing
December 12, 2013

GlaxoSmithKline plans to expand its facilities in Ware and Worthing in the United Kingdom and will build a new facility for manufacturing innovation.

Applying Catalysis to Optimize API Synthesis
December 4, 2013

Fine-chemical companies, contract manufacturers, and researchers advance chemocatalysis and biocatalysis.

ADVERTISEMENT

LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
What impact do mega-mergers of biopharmaceutical companies have on the development of new drugs?
Improves the quality and number of innovative drugs available to patients.
Restricts innovation and the development of new drugs.
Has no impact on drug development.
Do not know.
Improves the quality and number of innovative drugs available to patients.
29%
Restricts innovation and the development of new drugs.
54%
Has no impact on drug development.
4%
Do not know.
13%
Eric Langer Outsourcing Outlook Eric LangerOutsourcing No Longer Just for Cost-Cutting
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerSeeking Alternative Catalyst Solutions
Jill Wechsler Regulatory Watch Jill Wechsler Global Expansion Shapes Drug Oversight
Chris Burgess Statistical Solutions Chris BurgessIs a Sample Size of n=6 a Magic Number?
Sean Milmo European Regulatory WatchSean MilmoRegulating the Environmental Impact of Pharmaceuticals
FindPharma Custom Search
Click here